Physicians' Academy for Cardiovascular Education

Angiotensin receptor-neprilysin inhibitor reduces HbA1c levels

New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes

Presented at ACC.17 by Jelena Seferovic

News - Mar. 21, 2017

Main results


Treatment of HFrEF diabetes patients with sacubitril/valsartan was associated with greater reductions in HbA1c compared with enalapril treatment. Moreover, fewer sacubitril/valsartan-treated patients needed initiation of insulin therapy. These data suggest that, in addition to providing HF benefit, sacubitril/valsartan helps to tighten glycemic control among HF patients with diabetes. This beneficial metabolic effect is most likely secondary to the inhibition of neprilysin and consequent modulation of its circulating substrates and should be further investigated.


Our coverage of ACC.17 is based on the information provided during the congress.

This study was simultaneously published in The Lancet Diabetes & Endocrinology

Share this page with your colleagues and friends: